“Baseline Characteristics in Patients with Atopic Dermatitis from the North American Prospective Observational Study of Lebrikizumab (ADjoy)”, J of Skin, vol. 10, no. 2, p. s734, Mar. 2026, doi: 10.25251/djee0862.